BillionToOne Unveils Groundbreaking Findings at Upcoming AACR 2025 Meeting
BillionToOne Showcases Revolutionary Data at AACR 2025
BillionToOne, a leader in molecular diagnostics, is preparing to present compelling new data at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago from April 25 to 30. The company is dedicated to enhancing the accessibility of accurate diagnostic tests, focusing particularly on innovations in liquid biopsy technology.
At the core of their upcoming presentations are three key abstracts that highlight the advancements made in liquid biopsy methodologies, crucial for cancer detection and monitoring. The first presentation, titled "Tumor fraction estimation and tissue copy number inference using copy number signal from a liquid biopsy assay," will take place on April 29 from 9 AM to 12 PM, in Poster Section 20. This research emphasizes the capability of using liquid biopsies to draw inferences about tissue characteristics via mutations detected in circulating tumor DNA (ctDNA).
The second abstract, "Detection of a novel GNA11 processed pseudogene from cfDNA and implications for liquid biopsy," will be presented the same day from 2 PM to 5 PM in Poster Section 31. This innovation could significantly influence how non-tumor derived genetic material is understood and utilized in diagnostics, potentially leading to breakthroughs in cancer therapy decision-making.
Lastly, the third presentation, "Circulating cell-free methylated tumor DNA measurements correlate with plasma VAF-based tumor fraction estimates," also scheduled for April 29 from 2 PM to 5 PM in Poster Section 32, demonstrates the alignment between ctDNA measurements and traditional plasma-based tumor fraction estimates, further validating the effectiveness of these liquid biopsies in clinical settings.
Dr. Gary Palmer, who serves as Chief Medical Officer for Oncology at BillionToOne, shared his thoughts on these developments: "These data presented at AACR represent our dedication in advancing liquid biopsy testing with our proprietary single molecule precision technology and setting new standards in what can be achieved with plasma-based tests." He highlights how these advancements could drastically improve the success of ctDNA-based cancer profiling, ultimately guiding more accurate treatment options for patients.
BillionToOne, founded in Menlo Park, California, is on a mission to transform molecular diagnostics. Their proprietary single-molecule NGS (smNGS) platform, which includes the patented Quantitative Counting Template (QCT) technology, enables the counting of DNA molecules at an unparalleled precision. This innovation is vital in ensuring that the data they present can significantly affect the landscape of cancer diagnostics and treatment.
For anyone intrigued by advancements in medical technology and cancer treatment, the presentations at AACR 2025 promise to deliver exciting insights that could shape the future of healthcare. As BillionToOne continues to push the envelope in molecular diagnostics, their contributions are expected to pave the way for better patient outcomes in oncology. For more information on BillionToOne and its innovations, visit www.billiontoone.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.